Clinical Trial Update: A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II trial update reporting results for sorafenib in metastatic, androgen-independent prostate cancer (CRPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-09-28